Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer.
Virtually all cases of cervical cancer and its precursor intra-epithelial lesions are a result of infection with one or other of a subset of genital human papillomaviruses (HPVs), suggesting that prevention of HPV infection by prophylactic vaccination would be a highly effective anticancer strategy. Two HPV L1 virus-like particle vaccines have been developed, a quadrivalent HPV16/18/6/11 product and a bivalent HPV16/18 product; both have been shown to be highly immunogenic with a good safety profile and 100% efficacy against HPV16/18-related high-grade cervical intra-epithelial neoplasia (CIN2/3), implying that they will be effective at preventing HPV16/18-related cervical cancer.
Stanley
M
M
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK. mas@mole.bio.cam.ac.uk
D001005:Anus Neoplasms / Q000517:prevention & control / Q000821:virology*; D019049:Developed Countries; D003906:Developing Countries; D005260:Female; D006801:Humans; D015994:Incidence; D030361:Papillomavirus Infections / Q000276:immunology* / Q000517:prevention & control; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology*
D053918:Papillomavirus Vaccines